Edward Dyson

Ed counsels public and pre-IPO private companies, investors, entrepreneurs and underwriters on London Stock Exchange, Nasdaq and NYSE capital markets transactions.

• Incarichi

  Ed’s recent engagements include acting for:

  • VNV Global, as a major shareholder, on the Nasdaq de-SPACs of Swvl with Queen's Gambit Growth Capital and Gett with Rosecliff Acquisition Corp I
  • Kinnevik, as a major shareholder, on the Nasdaq de-SPAC of Babylon Health with Alkuri Global Acquisition
  • Heptares Therapeutics Limited, a wholly-owned subsidiary of Sosei Heptares Corporation, as a shareholder on the Nasdaq IPO of Centessa Pharmaceuticals plc
  • a selling shareholder on the Main Market IPO and standard listing of Deliveroo plc
  • Endava plc, a software development company, on its NYSE IPO
  • Renalytix AI plc, an artificial intelligence-enabled in vitro diagnostics company, on its demerger, AIM IPO and subsequent Nasdaq dual-listing
  • Kistos plc, a SPAC focused on energy transition, on its AIM IPO and subsequent reverse takeover of Tulip, associated placing, PrimaryBid offer, subscription and Norwegian listed bond offering
  • National World plc, a SPAC focused on news publishing, on its Main Market IPO and Standard listing, and subsequent reverse takeover of JPI Media and associated convertible loan note offering
  • Tiziana Life Sciences plc, a clinical-stage biopharmaceutical company, on its Nasdaq dual-listing and various global follow-on securities offerings
  • the underwriters on the Nasdaq IPO of Compass Pathways plc, a mental healthcare company
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, on its Nasdaq IPO and various follow-on securities offerings
  • Scancell Holdings plc, a clinical-stage biopharmaceutical company, on various AIM follow-on securities offerings
  • the underwriters on the aborted Nasdaq IPO of Horizon Discovery plc, an AIM-listed gene editing company
  • the underwriters on the Nasdaq IPO of Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company
  • Realm Therapeutics plc, a clinical-stage biopharmaceutical company, on its direct dual-listing on Nasdaq, subsequent AIM delisting and acquisition by Essa Pharma Inc. by way of scheme of arrangement
  • the underwriters on the aborted Nasdaq IPO of Kymab Limited, a clinical-stage biopharmaceutical company
  • the underwriters on various Nasdaq follow-on securities offerings by NuCana plc, a clinical-stage biopharmaceutical company
  • the underwriters on the aborted Nasdaq IPO of Mereo BioPharma Group plc, a clinical-stage biopharmaceutical company
  • RockRose Energy plc, an independent oil and gas company, on its readmission to the Main Market and Standard listing following the acquisition of the North Sea interests from Marathon Oil
  • OKYO Pharma Limited, a pre-clinical biopharmaceutical company, on its Main Market IPO and Standard listing, and associated equity placing and warrant issuance
  • MightyHive Inc., a data and digital media consultancy, on its acquisition by S4 Capital plc, a digital advertising and marketing company
  • Misys plc, a software company, on its aborted Main Market IPO and Premium listing
  • Just Retirement Group plc, a retirement financial solutions provider, on its standby underwritten follow-on offering, associated merger with Partnership Assurance Group plc, a non-standard annuity provider, and Main Market introduction and Premium listing of the combined entity, Just Group plc
  • B&M European Value Retail S.A. (B&M Stores), a European variety goods value retailer, on its Main Market IPO and Premium listing
  • the underwriters on the Main Market IPO and Premium listing of Metro Bank plc, a UK challenger bank
  • TCS Group Holding plc (Tinkoff Credit Systems), a Russian challenger bank, on its Main Market IPO and Standard listing
  • Romgaz S.A., a Romanian natural gas producer and supplier, on its Main Market IPO and Standard listing
  • Selling shareholders and underwriters on numerous secondary sale block trades

  Please note: Ed's experience includes that prior to joining Orrick.